Sudden sensorineural hearing loss and coronavirus disease 2019

Pool, Christopher; King, Tonya S.; Pradhan, Sandeep; Işıldak, Hüseyin

doi:10.1017/s0022215122000068

Cited by 6 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings support the idea that COVID-19 infections do not clinically significantly increase patients' risk of developing SSNHL. This work reinforces findings in studies from Israel and Massachusetts on ICD10 codes [5] , [6] , survey data of otolaryngologists on the perception of COVID-19's effect on SSNHL [9] , and a study testing for COVID-19 in patients presenting for SSNHL [4] . Interestingly, similar to the current work, other reports have also observed a decrease in rates of SSNHL during the pandemic, perhaps secondary to decreased exposure to common viruses that actually cause SSNHL [10] .…”

Section: Discussionsupporting

confidence: 85%

COVID-19 and transtympanic injections for sudden sensorineural hearing loss

Adams

Marinelli

Travis

et al. 2023

American Journal of Otolaryngology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 85%

COVID-19 and transtympanic injections for sudden sensorineural hearing loss

Adams

Marinelli

Travis

et al. 2023

American Journal of Otolaryngology

View full text Add to dashboard Cite

“…In a survey of more than 200 American otorhinolaryngologists in March 2021, most did not notice any rise in SSNHL incidence during the pandemic (Pool et al, 2022). Most studies exploring the incidence of SSNHL during the pandemic compared to before the pandemic found no difference (Aslan and Cicek, 2021;Chari et al, 2021;Chao and Young, 2022;Parrino et al, 2022).…”

Section: Sudden Sensorineural Hearing Lossmentioning

confidence: 99%

COVID-19 and hearing loss—A narrative review

Feng

Voruz

et al. 2023

Front. Audiol. Otol.

View full text Add to dashboard Cite

Interest in hearing loss associated with COVID-19 has increased since the pandemic started. Early on during the spread of SARS-CoV-2 across the globe, reports of smell and taste disorders secondary to COVID-19 emerged, and to a lesser extent, reports of sensorineural hearing loss also surfaced. This raised questions regarding changes in the epidemiology of hearing loss and modifications to otologic practice that have evolved in response to the COVID-19 pandemic. To elucidate these questions, we performed a comprehensive literature search, including articles up to November 2022, using “COVID hearing loss” in MEDLINE. A total of 153 articles were included for full-text review and data extraction. There are several proposed mechanisms through which COVID-19 may contribute to hearing loss—direct viral infection, microthrombi, or hemorrhage. There is a growing repository of case reports and series on SARS-CoV-2-associated sensorineural hearing loss, with variable quality. Most patients who experienced hearing loss did so within a month of infection, with most patients' symptoms resolving within 2 weeks. The growing body of literature discussing SARS-CoV-2-associated hearing loss does not suggest a significant rise in the occurrence of sensorineural or overall hearing loss. In this ongoing COVID-19 era, hearing loss should be approached in the same state-of-the-art manner as before the pandemic.

show abstract

“…Recent updates have pointed out the need for the long-term documentation of audiovestibular symptoms in large cohorts of SARS-CoV-2-infected patients before conclusions can be drawn about their true incidence [62][63][64]. On the basis of the existing literature, SSNHL can be considered so far as a rare complication of COVID-19 infection [21,65,66].…”

Section: Principal Findingsmentioning

confidence: 99%

Safety Signal Generation for Sudden Sensorineural Hearing Loss Following Messenger RNA COVID-19 Vaccination: Postmarketing Surveillance Using the French Pharmacovigilance Spontaneous Reporting Database

Thai-Van¹,

Valnet-Rabier²,

Anciaux³

et al. 2023

JMIR Public Health Surveill

View full text Add to dashboard Cite

Background The World Health Organization recently described sudden sensorineural hearing loss (SSNHL) as a possible adverse effect of COVID-19 vaccines. Recent discordant pharmacoepidemiologic studies invite robust clinical investigations of SSNHL after COVID-19 messenger RNA (mRNA) vaccines. This postmarketing surveillance study, overseen by French public health authorities, is the first to clinically document postvaccination SSNHL and examine the role of potential risk factors. Objective This nationwide study aimed to assess the relationship between SSNHL and exposure to mRNA COVID-19 vaccines and estimate the reporting rate (Rr) of SSNHL after mRNA vaccination per 1 million doses (primary outcome). Methods We performed a retrospective review of all suspected cases of SSNHL after mRNA COVID-19 vaccination spontaneously reported in France between January 2021 and February 2022 based on a comprehensive medical evaluation, including the evaluation of patient medical history, side and range of hearing loss, and hearing recovery outcomes after a minimum period of 3 months. The quantification of hearing loss and assessment of hearing recovery outcomes were performed according to a grading system modified from the Siegel criteria. A cutoff of 21 days was used for the delay onset of SSNHL. The primary outcome was estimated using the total number of doses of each vaccine administered during the study period in France as the denominator. Results From 400 extracted cases for tozinameran and elasomeran, 345 (86.3%) spontaneous reports were selected. After reviewing complementary data, 49.6% (171/345) of documented cases of SSNHL were identified. Of these, 83% (142/171) of SSNHL cases occurred after tozinameran vaccination: Rr=1.45/1,000,000 injections; no difference for the rank of injections; complete recovery in 22.5% (32/142) of cases; median delay onset before day 21=4 days (median age 51, IQR 13-83 years); and no effects of sex. A total of 16.9% (29/171) of SSNHL cases occurred after elasomeran vaccination: Rr=1.67/1,000,000 injections; rank effect in favor of the first injection (P=.03); complete recovery in 24% (7/29) of cases; median delay onset before day 21=8 days (median age 47, IQR 33-81 years); and no effects of sex. Autoimmune, cardiovascular, or audiovestibular risk factors were present in approximately 29.8% (51/171) of the cases. SSNHL was more often unilateral than bilateral for both mRNA vaccines (P<.001 for tozinameran; P<.003 for elasomeran). There were 13.5% (23/142) of cases of profound hearing loss, among which 74% (17/23) did not recover a serviceable ear. A positive rechallenge was documented for 8 cases. Conclusions SSNHL after COVID-19 mRNA vaccines are very rare adverse events that do not call into question the benefits of mRNA vaccines but deserve to be known given the potentially disabling impact of sudden deafness. Therefore, it is essential to properly characterize postinjection SSNHL, especially in the case of a positive rechallenge, to provide appropriate individualized recommendations.

show abstract

Sudden sensorineural hearing loss and coronavirus disease 2019

Cited by 6 publications

References 24 publications

COVID-19 and transtympanic injections for sudden sensorineural hearing loss

COVID-19 and transtympanic injections for sudden sensorineural hearing loss

COVID-19 and hearing loss—A narrative review

Safety Signal Generation for Sudden Sensorineural Hearing Loss Following Messenger RNA COVID-19 Vaccination: Postmarketing Surveillance Using the French Pharmacovigilance Spontaneous Reporting Database

Contact Info

Product

Resources

About